Literature DB >> 14614455

PCAF is a coactivator for p73-mediated transactivation.

Lisa Y Zhao1, Yue Liu, Nicholas R Bertos, Xiang-Jiao Yang, Daiqing Liao.   

Abstract

The tumor suppressor p53-related p73 shares significant amino-acid sequence identity with p53. Like p53, p73 recognizes canonical p53 DNA-binding sites and activates p53-responsive target genes and induces apoptosis. Moreover, transcription coactivator p300/CBP binds to and coactivates with both p53 and p73 in stimulating the expression of their target genes. Here, we report that coactivator PCAF binds to p73. The N-terminal transactivation domain (TAD) and the conserved oligomerization domain (OD) of p73 are both required for its interaction with PCAF. Conversely, PCAF's HAT-domain is required for and both the N-terminal region and Bromo domain enhance binding of PCAF to p73. Significantly, PCAF stimulates p73-mediated transactivation, and binding of PCAF to p73 is necessary for p73's transactivation activity. PCAF-specific siRNA dramatically reduces p73-mediated transactivation. Stimulation of p73-mediated transactivation by PCAF requires the HAT domain of PCAF and the p53-binding site within the p21 promoter. In vivo, coexpression of wild-type, but not HAT-deficient PCAF with p73beta markedly increases p21 expression. Furthermore, cotransfection of PCAF and p73 leads to increased apoptosis and reduced colony formation. Collectively, these data suggest that p73 recruit PCAF to specific promoters to activate the transcription of p73 target genes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14614455     DOI: 10.1038/sj.onc.1206916

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  A new coactivator function for Zac1's C2H2 zinc finger DNA-binding domain in selectively controlling PCAF activity.

Authors:  Anke Hoffmann; Dietmar Spengler
Journal:  Mol Cell Biol       Date:  2008-07-28       Impact factor: 4.272

Review 2.  Therapeutic prospects for p73 and p63: rising from the shadow of p53.

Authors:  Anna Vilgelm; Wael El-Rifai; Alexander Zaika
Journal:  Drug Resist Updat       Date:  2008-09-17       Impact factor: 18.500

3.  PCAF acetylates {beta}-catenin and improves its stability.

Authors:  Xinjian Ge; Qihuang Jin; Fang Zhang; Tingting Yan; Qiwei Zhai
Journal:  Mol Biol Cell       Date:  2008-11-05       Impact factor: 4.138

4.  Transcriptional activation of human matrix metalloproteinase-9 gene expression by multiple co-activators.

Authors:  Xueyan Zhao; Etty N Benveniste
Journal:  J Mol Biol       Date:  2008-09-04       Impact factor: 5.469

5.  Modeling human cancer-related regulatory modules by GA-RNN hybrid algorithms.

Authors:  Jung-Hsien Chiang; Shih-Yi Chao
Journal:  BMC Bioinformatics       Date:  2007-03-14       Impact factor: 3.169

6.  RACK1 is a candidate gene associated with the prognosis of patients with early stage non-small cell lung cancer.

Authors:  Yi-Young Choi; Shin Yup Lee; Won Kee Lee; Hyo-Sung Jeon; Eung Bae Lee; Hyun Cheol Lee; Jin Eun Choi; Hyo-Gyoung Kang; Eun Jin Lee; Eun Young Bae; Seung Soo Yoo; Jaehee Lee; Seung Ick Cha; Chang Ho Kim; In-San Kim; Myung Hoon Lee; Young Tae Kim; Sanghoon Jheon; Jae Yong Park
Journal:  Oncotarget       Date:  2015-02-28

7.  Association of the circadian factor Period 2 to p53 influences p53's function in DNA-damage signaling.

Authors:  Tetsuya Gotoh; Marian Vila-Caballer; Jingjing Liu; Samuel Schiffhauer; Carla V Finkielstein
Journal:  Mol Biol Cell       Date:  2014-11-19       Impact factor: 4.138

Review 8.  p53 Family and Cellular Stress Responses in Cancer.

Authors:  Johanna Pflaum; Sophie Schlosser; Martina Müller
Journal:  Front Oncol       Date:  2014-10-21       Impact factor: 6.244

Review 9.  Distinct p63 and p73 Protein Interactions Predict Specific Functions in mRNA Splicing and Polyploidy Control in Epithelia.

Authors:  Julian M Rozenberg; Olga S Rogovaya; Gerry Melino; Nickolai A Barlev; Alexander Kagansky
Journal:  Cells       Date:  2020-12-25       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.